NEXIEN BIOPHARMA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0168 USD | -17.04% |
|
-42.07% | -35.14% |
| Sales 2022 | - | Sales 2023 | - | Capitalization | 2.29M 3.13M |
|---|---|---|---|---|---|
| Net income 2022 | - 0 | Net income 2023 | - 0 | EV / Sales 2022 | - |
| Net Debt 2022 | 105K 143K | Net Debt 2023 | 236K 323K | EV / Sales 2023 | - |
| P/E ratio 2022 |
-5.77
x | P/E ratio 2023 |
-6.16
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 45.9% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -17.04% | ||
| 1 week | -42.07% | ||
| Current month | +3.07% | ||
| 1 month | -17.65% | ||
| 3 months | -16.00% | ||
| 6 months | -26.96% | ||
| Current year | -35.14% |
1 week
0.02
0.03
1 month
0.020.03
Current year
0.010.04
1 year
0.010.10
3 years
0.010.20
5 years
0.010.45
10 years
0.016.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 75 | 14-01-31 | |
Evan Wasoff
DFI | Director of Finance/CFO | 77 | - |
Jeremy Reeh
CTO | Chief Tech/Sci/R&D Officer | - | 18-10-25 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Lindy Snider
BRD | Director/Board Member | 64 | 18-01-25 |
| Chief Executive Officer | 75 | 14-01-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 0.0168 | -17.04% | 4,032 |
| 24-04-25 | 0.0202 | -2.99% | 1,221 |
| 24-04-24 | 0.0209 | -28.02% | 5,914 |
| 24-04-23 | 0.029 | +77.91% | 9,459 |
| 24-04-22 | 0.0163 | -43.79% | 6,001 |
Delayed Quote OTC Markets, April 26, 2024 at 02:30 pm
More quotes
Nexien BioPharma, Inc. is engaged in pre-clinical and drug development activities for certain pharmaceutical formulations that include cannabinoids. The Company is focused on developing and commercializing United States Food and Drug Administration (FDA)-compliant cannabinoid pharmaceuticals, drug delivery systems, and related technologies for diseases, disorders and medical conditions. Its flagship research and development programs are focused on advancing formulations that have the potential to improve the treatment outcomes of certain convulsive disorders and neuromuscular disorders, which includes the treatment of myotonic dystrophy. The Company's wholly owned subsidiaries include Intiva BioPharma Inc., NexN Inc. (NexN) and NexDM Inc.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| -35.14% | 1.13M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- NXEN Stock
